Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies

#1821

Introduction: LAN 120mg has been shown to significantly prolong progression-free survival (PFS) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Aim(s): To examine the long-term efficacy and safety of LAN in pts from the CLARINET and OLE studies.

Materials and methods: Pts with moderately- or well-differentiated, locally advanced or metastatic nonfunctioning GEP-NETs were randomized to LAN 120mg (n=101) or placebo (PB n=103) every 28 days for 96 weeks (wks). Pts from participating OLE centers with centrally assessed (RECIST 1.0) stable disease at 96 wks (n=56 [LAN, n=41; PB, n=15]) or progressive disease (n=32; PB only) during core study were eligible to receive LAN 120mg every 28 days in the OLE. PFS and overall survival (OS) were analyzed using Kaplan-Meier methods.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Phan A

Authors: Phan A, Pavel M, Caplin M, Wolin E, Mirakhur B,

Keywords: lanreotide,